Abstract：Objective To analyze the clinical effect of Zoledronic Acid combined with chemotherapy treating bone metastasis of non-small cell lung cancer(NSCLC),in order to provide reference for the selection of clinical treatment.Methods The clinical data of 82 patients with NSCLC bonemetastasiswho were treated in our hospital from January 1,2018 to January 1,2019 were analyzed retrospectively.According to the different treatmentmethods,they were divided into two groups.A total of 39 patients who received conventional chemotherapy were set as the control group and 43 patientswho received chemotherapy and Zoledronic Acid as the observation group.The clinical effect,bone pain score and adverse reactions were observed.Results The disease control rate of the observation group(93.02%)was higher than that of the control group(76.92%),the differencewas statistically significant(P＜0.05).Before treatment,there was no significant difference between the two groups in numeric rating scale(NRS)score(P＞0.05).After treatment,the NRS scores of both groups were lower than those before treatment,the NRSscore of the observation group([1.42±0.91]points)was lower than that of the control group([2.59±1.27]points),the differences were statistically significant(P＜0.05).The incidence rates of gastrointestinal reactions,bonemarrow suppression and fever in the observation group and the control group were compared(23.26%vs.30.77%,20.93%vs.17.95%,11.63%vs.7.69%),with no significant difference(P＞0.05).Conclusion Zoledronic Acid combined with chemotherapy treating NSCLC bonemetastasis can improve the symptoms of bone pain,inhibit the growth and progress of tumor,and improve the therapeutic effect without increasing adverse reactions.
京公网安备 11010502046607号